Preliminary report of clinical experience with metal-on-highly-crosslinked-polyethylene hip resurfacing.

Objectives: Modern metal-on-metal (MoM) hip resurfacing arthroplasty (HRA), while achieving good results with well-orientated, well-designed components in ideal patients, is contraindicated in women, men with head size under 50 mm, or metal hypersensitivity. These patients currently have no access to the benefits of HRA. Highly crosslinked polyethylene (XLPE) has demonstrated clinical success in total hip arthroplasty (THA) and, when used in HRA, potentially reduces metal ion-related sequelae.

Failure of a novel ceramic-on-ceramic hip resurfacing prosthesis.

We report the early failure of five ceramic-on-ceramic hip resurfacings (CoCHRs). The ceramic used for the acetabular liner was a novel ceramic-composite (two thirds polyurethane and one third alumina ceramic). All cases were revised for increasing metal ion levels (blood cobalt 3.

What are the risks accompanying the reduced wear benefit of low-clearance hip resurfacing?

Background: Clearance is an important determinant of metal-metal bearing function. Tribologic theory and laboratory evidence suggest low clearance (LC) reduces wear but with a potential to increase friction and clinical reports show LC resurfacings have high implant failure rates. Thus, the role of LC is unclear.

Is mid-head resection a durable conservative option in the presence of poor femoral bone quality and distorted anatomy?

Background: High medium-term survivorship of hip resurfacing arthroplasty in young patients has led to its increased usage. To achieve high survival rates, selecting patients with appropriate proximal femoral morphology and bone quality is important. For patients with poor bone quality or abnormal morphology, the mid-head resection technique is an alternative, bone-conserving procedure but whether this technique results in acceptable complications and survival is unknown.

Early markers of nephrotoxicity in patients with metal-on-metal hip arthroplasty.

Background: Metal ions released from arthroplasty devices are largely cleared in urine, leading to high exposure in renal tissues. Validated early markers of renal damage are routinely used to monitor workers in heavy metal industries, and renal risk can be quantified in these industries. It is unclear if the ion levels in patients with metal-on-metal hips are sufficient to cause renal damage.

Renal clearance of cobalt in relation to the use of metal-on-metal bearings in hip arthroplasty.

Background: A concern regarding the use of metal-on-metal bearings in hip arthroplasty has been that the high levels of metal ions that are released overwhelm the renal threshold for metal excretion, leading to systemic buildup of metals. The purpose of this investigation was to determine if the physiological renal capacity for cobalt clearance and cobalt concentrating efficiency is overwhelmed by the elevation in metal ion levels seen in patients with metal-on-metal-bearing hip devices.

Methods: Concurrent specimens of urine and plasma were obtained from a group of 461 patients (346 men and 115 women) at various intervals after either a unilateral (296) or a bilateral (130) metal-on-metal hip arthroplasty or preoperatively (thirty-five patients; the control specimens).

A clinicoradiologic study of the Birmingham Mid-Head Resection device.

This is a 1.2- to 5.3-year survival and clinicoradiologic study of patients with the Birmingham Mid-Head Resection (BMHR) device (Smith & Nephew Orthopaedics, Warwick, United Kingdom).

Systemic metal exposure in large- and small-diameter metal-on-metal total hip replacements.

Large-diameter metal-metal total hip replacement (THR) offers the advantages of low wear and low dislocation risk. the aim of this investigation was to compare metal levels in large and small-diameter metal-metal hip replacements. Whole blood concentrations and daily output of cobalt and chromium in 28 patients with unilateral large diameter (42- to 54-mm) metal on metal hip replacements at 1-year follow-up were compared with levels in patients with 28-mm metal-on-metal THRs.